首页> 外文期刊>Science >Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination
【24h】

Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination

机译:通过疫苗诱导广泛中和的H1N1流感抗体

获取原文
获取原文并翻译 | 示例
       

摘要

The rapid dissemination of the 2009 pandemic influenza virus underscores the need for universal influenza vaccines that elicit protective immunity to diverse viral strains. Here, we show that vaccination with plasmid DNA encoding H1N1 influenza hemagglutinin (HA) and boosting with seasonal vaccine or replication-defective adenovirus 5 vector encoding HA stimulated the production of broadly neutralizing influenza antibodies. This prime/boost combination increased the neutralization of diverse H1N1 strains dating from 1934 to 2007 as compared to either component alone and conferred protection against divergent H1N1 viruses in mice and ferrets. These antibodies were directed to the conserved stem region of HA and were also elicited in nonhuman primates. Cross-neutralization of H1N1 subtypes elicited by this approach provides a basis for the development of a universal influenza vaccine for humans.
机译:2009年大流行性流感病毒的迅速传播突显了对通用流感疫苗的需求,这种疫苗可引发对多种病毒株的保护性免疫。在这里,我们显示,用编码H1N1流感血凝素(HA)的质粒DNA进行疫苗接种,并用季节性疫苗或编码HA的复制缺陷型腺病毒5载体加强免疫,可刺激产生广泛中和的流感抗体。与单独使用任一组分相比,这种初次/加强免疫组合可增强1934年至2007年间多种H1N1病毒株的中和作用,并能在小鼠和雪貂中抵抗多种H1N1病毒。这些抗体针对HA的保守茎区域,并且也在非人灵长类动物中诱发。通过这种方法引起的H1N1亚型的交叉中和为人类通用流感疫苗的开发提供了基础。

著录项

  • 来源
    《Science》 |2010年第5995期|P.1060-1064|共5页
  • 作者单位

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-3005, USA;

    rnVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-3005, USA;

    rnVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-3005, USA;

    rnVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-3005, USA;

    rnInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA;

    rnVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-3005, USA;

    rnBIOQUAL, Rockvitle, MD 20850, USA;

    rnVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-3005, USA;

    rnInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA;

    rnVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-3005, USA;

    rnVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-3005, USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:37

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号